Available Technology

Sialostatin Mediation Controls Blood-feeding Success of the TickIxodes scapularis

This invention offers an environmentally friendly alternative to existing acaricides (pesticides), and relates to vaccines against tick bites and the pathogens that the ticks may transmit. Bites from the nymphal stage ofIxodes scapularisare associated with Lyme disease transmission in disease-endemic areas of central and eastern US.Ixodes scapularisnymphs are the key vector stage implicated in Lyme disease transmission, mainly due to their small size that makes timely detection difficult. Guinea pig vaccination against sialostatin L2, a secretedIxodes scapularissalivary protein, can confer nymphal recognition and protection against the tick. Increased rejection rates, prolonged feeding time, and inflammation were observed in the vaccine group, indicating that a protective host immune response was elicited. Moreover, anti-sialostatin L2 titers correlate with weight reduction of nymphs by the end of feeding. These studies suggest that an essential action of sialostatin L2 can be blocked by host humoral immunity.
Benefits: 
Sialostatin L2 as an anti-tick vaccine will target the vector and therefore confer protection against all the pathogens that may be transmitted by the vector. -An environmentally friendly alternative to acaricides.
applications: 
Inventors: 
Michail Kotsyfakis
Patent Number: 
60/963,332
Internal Laboratory Ref #: 
E-289-2007/0
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin